Fill the Discovery Funnel with Quality Hits Using Label-Free, Multiplexed Mass-Spectrometry and Safety Assays with the Genedata Screener Analysis Platform - SLAS2023
New assay formats and detection technologies can help fill the R&D pipeline with quality candidates from the start. Due to the more complex data they produce, they require an up-to-date analysis platform to unfold their potential. Thus, biopharmaceutical companies around the world rely on Genedata Screener® as an out-of-the box platform that streamlines, scales up, and standardizes the analysis of such assay data −automating everything from data import to result reporting. In this tutorial, we will present two new applications that are being enabled with the new Screener version 20.
Mass spectrometry (MS) continues to deliver better screening results in less time. It is an ideal platform for rapid, cheap, scalable assays due to its highly sensitive label-free readout, fast instrumentation, and its amenability across many molecular modalities. The increasing throughput and assay complexity has its toll--data analysis has become the limiting factor. Genedata Screener® overcomes this limitation with new, ready-to-go analysis workflows for the typical assay formats--multiplexed affinity selection MS, covalent binding screening, and multiple reaction monitoring. Here we present how these workflows allow MS screening labs to scale up and speed up their assays, to shorten project cycles.
Early toxicity screening of hit and lead candidates in physiologically relevant models has become reality with advancements in iPSC technology and calcium oscillation assays, enabling monitoring calcium signaling in cardiomyocytes and neuronal cells at relatively low cost. Again, scaling up these cellular models to higher throughput creates a new challenge with respect to analysis of these high-volume, complex data. To address this challenge, Genedata Screener® now features a new automated workflow for high-throughput analysis of calcium oscillation data together with an extended support for analysis of automated patch clamp data (e.g. CiPA-mandated assays). We will show how this workflow allows automated parallel processing of entire screening runs for detecting different forms of cardiac liabilities.
Presented by: Matthias Fassler, Head of Product Management, Genedata